155 related articles for article (PubMed ID: 37741509)
1. Deep Learning Can Predict Bevacizumab Therapeutic Effect and Microsatellite Instability Directly from Histology in Epithelial Ovarian Cancer.
Wang CW; Lee YC; Lin YJ; Firdi NP; Muzakky H; Liu TC; Lai PJ; Wang CH; Wang YC; Yu MH; Wu CH; Chao TK
Lab Invest; 2023 Nov; 103(11):100247. PubMed ID: 37741509
[TBL] [Abstract][Full Text] [Related]
2. Weakly supervised deep learning for prediction of treatment effectiveness on ovarian cancer from histopathology images.
Wang CW; Chang CC; Lee YC; Lin YJ; Lo SC; Hsu PC; Liou YA; Wang CH; Chao TK
Comput Med Imaging Graph; 2022 Jul; 99():102093. PubMed ID: 35752000
[TBL] [Abstract][Full Text] [Related]
3. Mismatch-repair deficiency, microsatellite instability, and lynch syndrome in ovarian cancer: A systematic review and meta-analysis.
Mitric C; Salman L; Abrahamyan L; Kim SR; Pechlivanoglou P; Chan KKW; Gien LT; Ferguson SE
Gynecol Oncol; 2023 Mar; 170():133-142. PubMed ID: 36682091
[TBL] [Abstract][Full Text] [Related]
4. Interpretable attention-based deep learning ensemble for personalized ovarian cancer treatment without manual annotations.
Wang CW; Lee YC; Lin YJ; Chang CC; Sai AK; Wang CH; Chao TK
Comput Med Imaging Graph; 2023 Jul; 107():102233. PubMed ID: 37075618
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.
Al Wadi K; Ghatage P
Expert Opin Pharmacother; 2016; 17(6):853-60. PubMed ID: 26933765
[TBL] [Abstract][Full Text] [Related]
6. Ovarian endometrioid adenocarcinoma: incidence and clinical significance of the morphologic and immunohistochemical markers of mismatch repair protein defects and tumor microsatellite instability.
Aysal A; Karnezis A; Medhi I; Grenert JP; Zaloudek CJ; Rabban JT
Am J Surg Pathol; 2012 Feb; 36(2):163-72. PubMed ID: 22189970
[TBL] [Abstract][Full Text] [Related]
7. c-MET/VEGFR-2 co-localisation impacts on survival following bevacizumab therapy in epithelial ovarian cancer: an exploratory biomarker study of the phase 3 ICON7 trial.
Morgan RD; Ferreras C; Peset I; Avizienyte E; Renehan AG; Edmondson RJ; Murphy AD; Nicum S; Van Brussel T; Clamp AR; Lambrechts D; Zhou C; Jayson GC
BMC Med; 2022 Feb; 20(1):59. PubMed ID: 35144591
[TBL] [Abstract][Full Text] [Related]
8. Tumor site discordance in mismatch repair deficiency in synchronous endometrial and ovarian cancers.
Kim SR; Tone A; Kim R; Cesari M; Clarke B; Eiriksson L; Hart T; Aronson M; Holter S; Lytwyn A; Maganti M; Oldfield L; Gallinger S; Bernardini MQ; Oza AM; Djordjevic B; Lerner-Ellis J; Van de Laar E; Vicus D; Pugh TJ; Pollett A; Ferguson SE
Int J Gynecol Cancer; 2020 Dec; 30(12):1951-1958. PubMed ID: 33082239
[TBL] [Abstract][Full Text] [Related]
9. PPsNet: An improved deep learning model for microsatellite instability high prediction in colorectal cancer from whole slide images.
Lou J; Xu J; Zhang Y; Sun Y; Fang A; Liu J; Mur LAJ; Ji B
Comput Methods Programs Biomed; 2022 Oct; 225():107095. PubMed ID: 36057226
[TBL] [Abstract][Full Text] [Related]
10. Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.
Gadducci A; Guarneri V; Peccatori FA; Ronzino G; Scandurra G; Zamagni C; Zola P; Salutari V
J Ovarian Res; 2019 Jan; 12(1):9. PubMed ID: 30691488
[TBL] [Abstract][Full Text] [Related]
11. Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger.
Jensen KC; Mariappan MR; Putcha GV; Husain A; Chun N; Ford JM; Schrijver I; Longacre TA
Am J Surg Pathol; 2008 Jul; 32(7):1029-37. PubMed ID: 18469706
[TBL] [Abstract][Full Text] [Related]
12. Correlation between germline mutations in MMR genes and microsatellite instability in ovarian cancer specimens.
Akbari MR; Zhang S; Cragun D; Lee JH; Coppola D; McLaughlin J; Risch HA; Rosen B; Shaw P; Sellers TA; Schildkraut J; Narod SA; Pal T
Fam Cancer; 2017 Jul; 16(3):351-355. PubMed ID: 28176205
[TBL] [Abstract][Full Text] [Related]
13. Histopathological whole slide image dataset for classification of treatment effectiveness to ovarian cancer.
Wang CW; Chang CC; Khalil MA; Lin YJ; Liou YA; Hsu PC; Lee YC; Wang CH; Chao TK
Sci Data; 2022 Jan; 9(1):25. PubMed ID: 35087101
[TBL] [Abstract][Full Text] [Related]
14. Deep learning model for the prediction of microsatellite instability in colorectal cancer: a diagnostic study.
Yamashita R; Long J; Longacre T; Peng L; Berry G; Martin B; Higgins J; Rubin DL; Shen J
Lancet Oncol; 2021 Jan; 22(1):132-141. PubMed ID: 33387492
[TBL] [Abstract][Full Text] [Related]
15. Patterns of First-Line Systemic Therapy Delivery and Outcomes in Advanced Epithelial Ovarian Cancer in Ontario.
Liu SL; Chan WC; Bouchard-Fortier G; Lheureux S; Ferguson SE; Krzyzanowska MK
Curr Oncol; 2022 Aug; 29(8):5988-6009. PubMed ID: 36005210
[TBL] [Abstract][Full Text] [Related]
16. A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy.
Kang J; D'Andrea AD; Kozono D
J Natl Cancer Inst; 2012 May; 104(9):670-81. PubMed ID: 22505474
[TBL] [Abstract][Full Text] [Related]
17. Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective study.
Farolfi A; Scarpi E; Greco F; Bergamini A; Longo L; Pignata S; Casanova C; Cormio G; Bologna A; Orditura M; Zavallone L; Attademo L; Gallà V; Franzese E; Pigozzi E; Loizzi V; Giorda G; Giardina D; Cioffi R; De Giorgi U
Sci Rep; 2020 Oct; 10(1):18190. PubMed ID: 33097745
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of Maintenance Therapy Based on Molecular Classification Following Treatment of Primary Epithelial Ovarian Cancer in the United States.
Penn CA; Wong MS; Walsh CS
JAMA Netw Open; 2020 Dec; 3(12):e2028620. PubMed ID: 33295974
[TBL] [Abstract][Full Text] [Related]
19. Deep learning-based methods for classification of microsatellite instability in endometrial cancer from HE-stained pathological images.
Zhang Y; Chen S; Wang Y; Li J; Xu K; Chen J; Zhao J
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8877-8888. PubMed ID: 37150803
[TBL] [Abstract][Full Text] [Related]
20. Atezolizumab and Bevacizumab Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via Suppressing Epithelial-Mesenchymal Transition.
Zhang L; Chen Y; Li F; Bao L; Liu W
Front Immunol; 2019; 10():867. PubMed ID: 31105696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
